74075-29-9

Upstream product

• 74075-27-7 2-<2-(1,3-dioxolan-2-yl)ethyl>-2-<(1S)-1-phthalimido-2-phenylethyl>-1,3-dioxolane 
• 74075-26-6 2-(3-oxo-5-phenyl-(4S)-4-phthalimidopentyl)-1,3-dioxolane 
• 33861-65-3 N-phthaloyl-L-phenylalanine-2-mercaptopyridyl thioester 
• 98-88-4 benzoyl chloride 
• 74075-28-8 (S)-1-[2-(2-[1,3]Dioxolan-2-yl-ethyl)-[1,3]dioxolan-2-yl]-2-phenyl-ethylamine 

Downstream Products

• 74075-30-2 3-[2-((S)-1-Benzoylamino-2-phenyl-ethyl)-[1,3]dioxolan-2-yl]-propionic acid 
• 74075-32-4 (5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenyl-hexanoyl-L-proline benzyl ester 
• 74075-31-3 (5S)-5-[(N-benzoyl)amino]-4-oxo-6-phenyl-hexanoic acid 
• 74075-33-5 SRI-20 

Relevant academic research and scientific papers

Synthesis and biological activity of a ketomethylene analogue of a tripeptide inhibitor of angiotensin converting enzyme

An analogue of a tripeptide inhibitor of angiotensin converting enzyme, Bz-Phe-Gly-Pro, has been synthesized in which the amide bond connecting phenylalanine and glycine has been replaced by a ketomethylene group. This nonpeptide analogue, 20, shows more potent converting enzyme inhibiting activity, I50=0.07 μM, than Bz-Phe-Gly-Pro, I50=9.4 μM, or than the orally active D-3-mercapto-2-methylpropanoyl-L-proline (captopril, 1)I50=0.30 μM. Compound 20 has a K(i)of 1.06 x 10-7 and either competitive or noncompetitive enzyme kinetics depending on what substrate is used in the converting enzyme assay. In tests for inhibition of angiotensin I induced contractions in the guinea pig ileum, 20 has one-tenth the activity of 1.